26.5 USD
-0.18 (-0.67%)
26.5 USD
0 (0%)
Overall BLFS gets a fundamental rating of 5 out of 10. We evaluated BLFS against 58 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for BLFS as it has an excellent financial health rating, but there are worries on the profitability. BLFS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BLFS had positive earnings in the past year.
BLFS had a positive operating cash flow in the past year.
BLFS had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: BLFS reported negative operating cash flow in multiple years.
1.2 Ratios
BLFS has a better Return On Assets (-0.82%) than 60.34% of its industry peers.
With a decent Return On Equity value of -0.91%, BLFS is doing good in the industry, outperforming 67.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.82% | ||
| ROE | -0.91% | ||
| ROIC | N/A |
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BLFS has a Gross Margin of 70.02%. This is amongst the best in the industry. BLFS outperforms 93.10% of its industry peers.
BLFS's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for BLFS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
2. Health
2.1 Basic Checks
BLFS does not have a ROIC to compare to the WACC, probably because it is not profitable.
BLFS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BLFS has been increased compared to 5 years ago.
The debt/assets ratio for BLFS has been reduced compared to a year ago.
2.2 Solvency
BLFS has an Altman-Z score of 19.27. This indicates that BLFS is financially healthy and has little risk of bankruptcy at the moment.
BLFS has a Altman-Z score of 19.27. This is amongst the best in the industry. BLFS outperforms 100.00% of its industry peers.
BLFS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 19.27 |
ROIC/WACCN/A
WACC10.07%
2.3 Liquidity
A Current Ratio of 4.66 indicates that BLFS has no problem at all paying its short term obligations.
BLFS has a better Current ratio (4.66) than 72.41% of its industry peers.
A Quick Ratio of 3.64 indicates that BLFS has no problem at all paying its short term obligations.
With a decent Quick ratio value of 3.64, BLFS is doing good in the industry, outperforming 65.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.66 | ||
| Quick Ratio | 3.64 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 123.36% over the past year.
BLFS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -24.98%.
Measured over the past years, BLFS shows a very strong growth in Revenue. The Revenue has been growing by 24.59% on average per year.
EPS 1Y (TTM)123.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
Revenue 1Y (TTM)-24.98%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-8.19%
3.2 Future
Based on estimates for the next years, BLFS will show a very strong growth in Earnings Per Share. The EPS will grow by 29.91% on average per year.
BLFS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.24% yearly.
EPS Next Y28%
EPS Next 2Y47.99%
EPS Next 3Y43.26%
EPS Next 5Y29.91%
Revenue Next Year-5.39%
Revenue Next 2Y4.22%
Revenue Next 3Y9.87%
Revenue Next 5Y16.24%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
BLFS is valuated quite expensively with a Price/Earnings ratio of 106.00.
The rest of the industry has a similar Price/Earnings ratio as BLFS.
BLFS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.15.
The Price/Forward Earnings ratio is 273.48, which means the current valuation is very expensive for BLFS.
BLFS's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 36.12. BLFS is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 106 | ||
| Fwd PE | 273.48 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BLFS is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 243.03 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BLFS does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as BLFS's earnings are expected to grow with 43.26% in the coming years.
PEG (NY)3.79
PEG (5Y)N/A
EPS Next 2Y47.99%
EPS Next 3Y43.26%
5. Dividend
5.1 Amount
BLFS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
26.5
-0.18 (-0.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners104.58%
Inst Owner Change-2.67%
Ins Owners2.2%
Ins Owner Change-0.86%
Market Cap1.27B
Revenue(TTM)88.83M
Net Income(TTM)-3.21M
Analysts83.75
Price Target32.74 (23.55%)
Short Float %6.55%
Short Ratio8.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)128.28%
Min EPS beat(2)72.55%
Max EPS beat(2)184.01%
EPS beat(4)4
Avg EPS beat(4)208.62%
Min EPS beat(4)72.55%
Max EPS beat(4)496.49%
EPS beat(8)7
Avg EPS beat(8)84.53%
EPS beat(12)8
Avg EPS beat(12)5.02%
EPS beat(16)10
Avg EPS beat(16)1.09%
Revenue beat(2)2
Avg Revenue beat(2)6.11%
Min Revenue beat(2)5.11%
Max Revenue beat(2)7.1%
Revenue beat(4)4
Avg Revenue beat(4)5.3%
Min Revenue beat(4)3.34%
Max Revenue beat(4)7.1%
Revenue beat(8)7
Avg Revenue beat(8)8.78%
Revenue beat(12)8
Avg Revenue beat(12)3.65%
Revenue beat(16)10
Avg Revenue beat(16)2.21%
PT rev (1m)2.56%
PT rev (3m)2.56%
EPS NQ rev (1m)-50.06%
EPS NQ rev (3m)12.53%
EPS NY rev (1m)0%
EPS NY rev (3m)-23.53%
Revenue NQ rev (1m)-6.17%
Revenue NQ rev (3m)-7.39%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 106 | ||
| Fwd PE | 273.48 | ||
| P/S | 14.29 | ||
| P/FCF | N/A | ||
| P/OCF | 75.37 | ||
| P/B | 3.59 | ||
| P/tB | 9.48 | ||
| EV/EBITDA | 243.03 |
EPS(TTM)0.25
EY0.94%
EPS(NY)0.1
Fwd EY0.37%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.35
OCFY1.33%
SpS1.85
BVpS7.38
TBVpS2.8
PEG (NY)3.79
PEG (5Y)N/A
Graham Number6.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.82% | ||
| ROE | -0.91% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.02% | ||
| FCFM | N/A |
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
F-Score6
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 298.5% | ||
| Cap/Sales | 19.51% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 353.72% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.66 | ||
| Quick Ratio | 3.64 | ||
| Altman-Z | 19.27 |
F-Score6
WACC10.07%
ROIC/WACCN/A
Cap/Depr(3y)80.15%
Cap/Depr(5y)101.86%
Cap/Sales(3y)10.07%
Cap/Sales(5y)11.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)123.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
EPS Next Y28%
EPS Next 2Y47.99%
EPS Next 3Y43.26%
EPS Next 5Y29.91%
Revenue 1Y (TTM)-24.98%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-8.19%
Revenue Next Year-5.39%
Revenue Next 2Y4.22%
Revenue Next 3Y9.87%
Revenue Next 5Y16.24%
EBIT growth 1Y95.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year328.14%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y97.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y342.36%
OCF growth 3YN/A
OCF growth 5Y47.44%
BIOLIFE SOLUTIONS INC / BLFS FAQ
What is the ChartMill fundamental rating of BIOLIFE SOLUTIONS INC (BLFS) stock?
ChartMill assigns a fundamental rating of 5 / 10 to BLFS.
What is the valuation status for BLFS stock?
ChartMill assigns a valuation rating of 2 / 10 to BIOLIFE SOLUTIONS INC (BLFS). This can be considered as Overvalued.
Can you provide the profitability details for BIOLIFE SOLUTIONS INC?
BIOLIFE SOLUTIONS INC (BLFS) has a profitability rating of 3 / 10.
What is the financial health of BIOLIFE SOLUTIONS INC (BLFS) stock?
The financial health rating of BIOLIFE SOLUTIONS INC (BLFS) is 8 / 10.
Can you provide the dividend sustainability for BLFS stock?
The dividend rating of BIOLIFE SOLUTIONS INC (BLFS) is 0 / 10 and the dividend payout ratio is 0%.